Russell Frank Company’s Atara Biotherapeutics ATRA Stock Holding History

Russell Frank Company’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-212	Closed	-$134K	–	2966
2015 Q4	$134K	Hold	212	–	–	﹤0.01%	2765
2015 Q3	$167K	Sell	212 -1,006	-83%	-$1.23M	﹤0.01%	2739
2015 Q2	$1.61M	Buy	+1,218	New	+$1.4M	﹤0.01%	2090

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Frank Company's ATRA Position: Q1 2016 in Review

Russell Frank Company sold out of Atara Biotherapeutics (ATRA) in Q1 2016, closing a stake of 212 shares — an estimated $134K sold.

Russell Frank Company first reported a position in ATRA in Q2 2015 and held it in 3 quarters. The position peaked at $1.61M in Q2 2015. 70 funds tracked by Wall St. Rank hold ATRA as of Q1 2016.

Russell Frank Company reported no remaining Atara Biotherapeutics position as of Q1 2016 after selling out during the quarter.
Russell Frank Company sold 212 Atara Biotherapeutics shares in Q1 2016, an estimated $134K.
Russell Frank Company first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 3 quarters.
Russell Frank Company's Atara Biotherapeutics position peaked at $1.61M in Q2 2015.
70 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.